title: Effect of glutamate-aspartate reperfusion on postischemic neonatal myocardium.
abstract: OBJECTIVE
  We postulated that L-glutamate- and L-aspartate-enriched perfusate would improve functional recovery of postischemic neonatal rabbit hearts.
  
  
  METHODS
  Isolated working neonatal rabbit hearts were perfused with Krebs-Henseleit buffer and then subjected to 1 hour of hypothermic cardioplegic arrest with St. Thomas' Hospital solution. Hearts were then reperfused with L-glutamate- and L-aspartate-enriched (20 mmol/L) Krebs-Henseleit buffer (AA-enriched Krebs-Henseleit buffer). Hearts reperfused with Krebs-Henseleit buffer alone acted as controls (experiment A). Another group of hearts underwent a similar protocol but were reperfused with the AA-enriched Krebs-Henseleit buffer with correction of the sodium content (experiment B).
  
  
  RESULTS
  Hearts reperfused with AA-enriched Krebs-Henseleit buffer showed a significant decrease in aortic flow at both 15 (p = 0.04) and 30 (p = 0.025) minutes compared with controls. Arrhythmias were frequent. Sodium content of the AA-enriched Krebs-Henseleit buffer was 174 +/- 0.5 mmol/L. In experiment B, hearts reperfused with the AA-enriched Krebs-Henseleit buffer with correction of the sodium content exhibited no difference in aortic flow and cardiac output at either 15 or 30 minutes (p = 0.95 and 0.5 and 0.48 and 0.78, respectively) compared with controls. No arrhythmias were observed. The sodium content of the AA-enriched Krebs-Henseleit buffer was 146 +/- 0.7 mmol/L.
  
  
  CONCLUSIONS
  A beneficial effect on functional recovery of neonatal hearts reperfused with AA-enriched Krebs-Henseleit buffer was not demonstrated.
authors.affiliation: Department of Surgery, University of British Columbia, Vancouver, Canada.
authors.forename: S S
authors.initials: SS
authors.lastname: Sett
authors.forename: H
authors.initials: H
authors.lastname: Tearle
authors.forename: J G
authors.initials: JG
authors.lastname: LeBlanc
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001224:Aspartic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D002314:Cardioplegic Solutions; D004195:Disease Models, Animal; D005947:Glucose / Q000627:therapeutic use; D018698:Glutamic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D006321:Heart / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D008955:Models, Cardiovascular; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000601:surgery*; D015425:Myocardial Reperfusion; D011817:Rabbits; D014325:Tromethamine / Q000627:therapeutic use
chemical_list: D002314:Cardioplegic Solutions; C074097:Krebs-Henseleit solution; D014325:Tromethamine; D001224:Aspartic Acid; D018698:Glutamic Acid; D005947:Glucose